CatalYm Announces Leadership Change

CatalYm Announces Leadership Change   Munich, Germany, October 11, 2024 – CatalYm...

Read More

GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers

Sabrina Genssler, Daniel Schaetzlein, Eugen Leo, Markus Haake and Christine Schuberth-Wagner /...

Read More

SHP-1 is a central mediator of GDF-15 mediated adhesion inhibition in T-cells

Markus Haake, Neha Vashist, Beatrice Haack, Birgitt Fischer, Kristin Eichler, Matthias Kist,...

Read More

FASEB Science Research Conferences - TGF-β Superfamily

July 21 - July 25, 2024

Read More

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition...

Read More

CatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...

CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...

Read More

CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...

CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...

Read More

GDF-15 contributes to proliferation and immune escape of malignant gliomas

P. Roth, M. Junker, I. Tritschler, M. Mittelbronn, Y. Dombrowski, S. N....

Read More